Table 1 Efficacy figures used for cost-effectiveness analysis. For efficacy against hospitalisations by MV, the efficacy against severe MA-LRTI was used. For efficacy against deaths by mAb, the efficacy against RSV LRTI hospitalisations was used
Product type | End point | Mean efficacy (95% CI) | Source |
|---|---|---|---|
MV (maternal vaccine) | Medically attended lower respiratory tract illness (MA-LRTI), first 90 days of life | 57.1 (14.7 to 79.8) | [20] |
MV | Severe MA-LRTI, first 90 days of life | 81.8 (40.6 to 96.3) | [20] |
mAb (monoclonal antibodies) | RSV MA-LRTI, first 151 days of life | 79.5 (65.9 to 87.7) (pooled estimate from [21]) | |
mAb | RSV LRTI hospitalisations, first 151 days of life | 77.3 (50.3 to 89.7) |